DR. MARI HUDSON
Dr. Hudson is a rheumatologist and epidemiologist at the Jewish General Hospital and Lady Davis Institute, and an Associate professor and Member of the Division of Experimental Medicine in the Department of Medicine at McGill. She pursues research in systemic autoimmune rheumatic diseases (SARD). She is a founding member of the Canadian Scleroderma Research Group (CSRG) which, since 2003, has involved 15 sites across Canada, 20 clinicians and 10 basic scientists, recruited over 1600 patients, secured over $4 million in funds from CIHR, FRSQ, industry and patient organizations, trained over 30 graduate and postdoctoral students and 40 summer students, contributed to over 100 peer-reviewed papers and become an internationally recognized scleroderma research program.
She has worked on a broad range of projects and contributed to landmark papers related to health-related quality of life, classification of disease, measures of disease status, renal crisis, lung disease, clinical correlates of autoantibody profiles, oral health abnormalities and psychosocial health issues in systemic sclerosis. In addition, given the rarity of the disease at hand, she has also established several international collaborations with leading scleroderma experts worldwide (International Scleroderma Renal Crisis Survey, Tri-nation (Canada, Houston, Australia) Scleroderma Cohort and International Systemic Sclerosis Inception Cohort (INSYNC)). She currently co-leads the Scleroderma Clinical Trials Consortium (SCTC) Working Group on scleroderma renal crisis.
Recently, she has developed new interests in epigenetic signatures and cellular therapies for scleroderma.